170 related articles for article (PubMed ID: 1356018)
1. Signal transduction by the neu/erbB-2 receptor: a potential target for anti-tumor therapy.
Stancovski I; Peles E; Ben Levy R; Lemprecht R; Kelman Z; Goldman-Michael R; Hurwitz E; Bacus S; Sela M; Yarden Y
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):95-103. PubMed ID: 1356018
[TBL] [Abstract][Full Text] [Related]
2. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
[TBL] [Abstract][Full Text] [Related]
3. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C gamma.
Peles E; Levy RB; Or E; Ullrich A; Yarden Y
EMBO J; 1991 Aug; 10(8):2077-86. PubMed ID: 1676673
[TBL] [Abstract][Full Text] [Related]
5. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.
Yarden Y
Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2569-73. PubMed ID: 1969636
[TBL] [Abstract][Full Text] [Related]
6. Biochemical analysis of the ligand for the neu oncogenic receptor.
Yarden Y; Peles E
Biochemistry; 1991 Apr; 30(14):3543-50. PubMed ID: 1672825
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
8. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity.
Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y
J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090
[TBL] [Abstract][Full Text] [Related]
9. Regulated coupling of the Neu receptor to phosphatidylinositol 3'-kinase and its release by oncogenic activation.
Peles E; Lamprecht R; Ben-Levy R; Tzahar E; Yarden Y
J Biol Chem; 1992 Jun; 267(17):12266-74. PubMed ID: 1351056
[TBL] [Abstract][Full Text] [Related]
10. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.
Guy PM; Carraway KL; Cerione RA
J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772
[TBL] [Abstract][Full Text] [Related]
11. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
[TBL] [Abstract][Full Text] [Related]
12. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships.
Peles E; Ben-Levy R; Tzahar E; Liu N; Wen D; Yarden Y
EMBO J; 1993 Mar; 12(3):961-71. PubMed ID: 8096177
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells.
Jallal B; Schlessinger J; Ullrich A
J Biol Chem; 1992 Mar; 267(7):4357-63. PubMed ID: 1347042
[TBL] [Abstract][Full Text] [Related]
14. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor.
Brown VI; Shah N; Smith R; Hellman M; Jarett L; Mikami Y; Cohen E; Qian X; Greene MI
DNA Cell Biol; 1994 Feb; 13(2):193-209. PubMed ID: 7910024
[TBL] [Abstract][Full Text] [Related]
15. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
16. Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Muthuswamy SK; Siegel PM; Dankort DL; Webster MA; Muller WJ
Mol Cell Biol; 1994 Jan; 14(1):735-43. PubMed ID: 7903421
[TBL] [Abstract][Full Text] [Related]
17. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
Dougall WC; Qian X; Greene MI
J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.
Stancovski I; Hurwitz E; Leitner O; Ullrich A; Yarden Y; Sela M
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8691-5. PubMed ID: 1717984
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products.
Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI
Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells.
Kraus MH; Fedi P; Starks V; Muraro R; Aaronson SA
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2900-4. PubMed ID: 8464905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
